Preliminary efficacy data reported suggest that the efficacy profile of cetrelimab may be consistent with known profiles of PD-1 inhibitors in melanoma [40–45], PD-L1-high NSCLC [7, 11, 46–49], and MSI-H CRC [14, 15, 50]. This evidence concerns the gene PDCD1 and melanoma.